A recent study has revealed that the chemical-induced activation of type I interferon (e.g., Ifnb1) signalling and immunogenic cell death potentiates the antitumour efficacy of anti-PD-1 antibody in syngeneic mouse tumour models of colon and bladder cancer.45 Since anti-PD-1 antibodies such as nivolumab and pembrolizumab are used for treating patients with melanoma and non–small cell lung cancer, it is reasonable to consider the induction of cytokine surges by targeting NGLY1 as a promising approach to enhance the efficacy of immune checkpoint therapies in these patients. The gene discussed is NGLY1; the disease is lung cancer.